1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Wilms% Tumor (Nephroblastoma) Global Clinical Trials Review, H1, 2016

Wilms' Tumor (Nephroblastoma) Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Wilms' Tumor (Nephroblastoma) Global Clinical Trials Review, H1, 2016" provides an overview of Wilms' Tumor (Nephroblastoma) clinical trials scenario. This report provides top line data relating to the clinical trials on Wilms' Tumor (Nephroblastoma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Wilms% Tumor (Nephroblastoma) Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Wilms' Tumor (Nephroblastoma) to Oncology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Wilms' Tumor (Nephroblastoma) to Oncology Clinical Trials 17
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Clinical Trials by End Point Status 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Top Companies Participating in Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials 25
Prominent Drugs 27
Latest Clinical Trials News on Wilms' Tumor (Nephroblastoma) 28
Apr 14, 2016: Juno Therapeutics Announces First clinical data for the WT-1 TCR product candidate, JTCR016 at the American Association for Cancer Research Annual Meeting 28
Clinical Trial Profile Snapshots 29
Appendix 90
Abbreviations 90
Definitions 90
Research Methodology 91
Secondary Research 91
About GlobalData 92
Contact Us 92
Disclaimer 92
Source 93

List of Tables
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials by Region, 2016* 6
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
Proportion of Wilms' Tumor (Nephroblastoma) to Oncology Clinical Trials, G7 Countries (%), 2016* 14
Wilms' Tumor (Nephroblastoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Wilms' Tumor (Nephroblastoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Wilms' Tumor (Nephroblastoma) to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials by Phase, 2016* 18
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 19
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 20
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 21
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 22
Wilms' Tumor (Nephroblastoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 23
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 24
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 26
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 27

List of Figures
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
Proportion of Wilms' Tumor (Nephroblastoma) to Oncology Clinical Trials, G7 Countries (%), 2016* 14
Wilms' Tumor (Nephroblastoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Wilms' Tumor (Nephroblastoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Wilms' Tumor (Nephroblastoma) to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 18
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 19
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 20
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 21
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 22
Wilms' Tumor (Nephroblastoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 23
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 24
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 25
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 27
GlobalData Methodology 91

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

Download Unlimited Documents from Trusted Public Sources

Breast Cancer Statistics in Africa

  • December 2016
    14 pages
  • Breast Cancer  

  • Africa  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Cancer Statistics in the UK

  • December 2016
    20 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

Related Market Segments :

Cancer
Lymphoma
Clinical Trial
Therapy

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.